中国P站

The field of nanomedicine has seen remarkable advancements in drug delivery, focusing on the rational design of nanoparticles to enhance therapeutic outcomes and minimize off-target effects. This involves tailoring nanoparticle properties through molecular pharmaceutics principles to achieve improved efficacy and reduced toxicity [1].

Self-assembled nanostructures, such as liposomes and polymeric micelles, are increasingly utilized for encapsulating and delivering hydrophobic drugs. Modifications in their composition or architecture significantly influence drug loading, release kinetics, and overall stability, underscoring the importance of understanding nano-interface interactions for optimized formulations [2].

Stimuli-responsive drug delivery systems represent a significant innovation, designed to release therapeutic payloads in response to specific biological triggers like pH, temperature, or enzymatic activity. The molecular design of polymers and conjugates enables controlled drug release, crucial for localized delivery and reducing systemic exposure [3].

The biopharmaceutical classification system (BCS) plays a pivotal role in drug development and formulation by assessing drug solubility and permeability. These key molecular pharmaceutics parameters are essential for predicting in vivo performance and simplifying formulation design, facilitating biowaivers and ensuring therapeutic equivalence [4].

Understanding the solid-state properties of drug substances, including polymorphism and amorphous forms, is vital for formulation development. Characterization of these states and the influence of molecular interactions on dissolution, stability, and manufacturing processes are critical for creating stable and effective oral dosage forms [5].

Excipients are fundamental in amorphous solid dispersions (ASDs) for enhancing the solubility and bioavailability of poorly soluble drugs. The molecular mechanisms by which excipients stabilize the amorphous state and prevent recrystallization, along with polymer-drug interactions and thermodynamic stability, are key to successful ASD formulation [6].

Porous materials, particularly mesoporous silica nanoparticles, offer unique advantages for controlled drug release. Manipulating pore size, surface functionalization, and drug loading capacity allows for sustained or triggered drug delivery, highlighting the significance of molecular engineering of porous frameworks [7].

The oral delivery of biologics presents considerable challenges, including enzymatic degradation and poor absorption. Advanced delivery systems like nanoparticles and microparticles are being developed to protect protein and peptide drugs in the gastrointestinal tract and improve their intestinal permeability [8].

Particle size and morphology profoundly influence the dissolution and bioavailability of orally administered drugs. Techniques such as micronization and nanoparticle formation are employed to modify drug release profiles, establishing quantitative relationships between physical characteristics and pharmaceutical performance for optimized formulations [9].

Computational modeling and simulation are increasingly applied in molecular pharmaceutics to predict drug behavior and optimize formulations. Techniques like molecular dynamics and QSPR provide insights into drug-excipient interactions, solubility, and release kinetics, guiding efficient formulation design [10].

Description

The rational design of nanomedicines for targeted drug delivery focuses on engineering nanoparticles with precise properties for enhanced therapeutic efficacy and reduced toxicity. This approach leverages molecular pharmaceutics principles to tailor nanoparticles, incorporating surface modifications, controlled release mechanisms, and targeted delivery strategies. Factors such as particle size, shape, and surface charge are critical determinants of cellular uptake and biodistribution, ultimately influencing the successful transport of drugs to disease sites [1].

Self-assembled nanostructures, including liposomes and polymeric micelles, are instrumental in the encapsulation and delivery of hydrophobic drugs. Research in this area explores how variations in lipid composition or polymer architecture can modulate drug loading capacity, release kinetics, and the overall stability of the nanocarrier. A deep understanding of molecular interactions at the nano-interface is essential for optimizing drug formulations and improving the bioavailability of poorly soluble compounds [2].

Stimuli-responsive drug delivery systems offer sophisticated control over drug release, responding to specific biological cues such as changes in pH, temperature, or enzymatic activity. The molecular design of polymers and conjugates is central to creating systems that undergo conformational changes or degradation, leading to precisely controlled drug release. This technology holds significant promise for localized drug delivery and the minimization of systemic side effects [3].

The biopharmaceutical classification system (BCS) provides a framework for understanding drug behavior in vivo, classifying drugs based on their solubility and permeability. These molecular pharmaceutics parameters are crucial for predicting how a drug will perform and for guiding formulation development. The BCS facilitates simplified formulation design, enables biowaivers, and ensures therapeutic equivalence across different formulations [4].

Investigating the solid-state properties of drug substances is paramount for successful pharmaceutical formulation. Polymorphism and amorphous forms significantly impact drug performance, and understanding the molecular interactions within the solid state is key to controlling dissolution rates, stability, and manufacturing processes. This knowledge is vital for developing stable and effective oral dosage forms [5].

Amorphous solid dispersions (ASDs) are a critical strategy for improving the solubility and bioavailability of poorly soluble drugs, with excipients playing a central role. The molecular mechanisms by which various excipients stabilize the amorphous state and prevent recrystallization are extensively studied. Polymer-drug interactions and thermodynamic stability are highlighted as crucial factors for successful ASD formulation [6].

Porous materials, particularly mesoporous silica nanoparticles, are being explored for their utility in controlled drug release applications. The ability to manipulate pore size, surface functionalization, and drug loading capacity enables the design of systems for sustained or triggered drug delivery. Molecular engineering of these porous frameworks is key to optimizing drug diffusion and encapsulation efficiency [7].

Formulating biologics for oral delivery poses unique challenges related to enzymatic degradation and low intestinal permeability. Advanced delivery systems, including nanoparticles and microparticles, are being developed to protect sensitive biologic drugs within the gastrointestinal environment and enhance their absorption across the intestinal epithelium [8].

The influence of particle size and morphology on drug dissolution and bioavailability is a critical aspect of oral drug delivery. Techniques like micronization and nanoparticle formation are employed to precisely control drug release profiles, establishing quantitative relationships between physical drug characteristics and their subsequent pharmaceutical performance, essential for formulation optimization [9].

Computational modeling and simulation are powerful tools in molecular pharmaceutics for predicting drug behavior and optimizing formulations. Methodologies such as molecular dynamics, Monte Carlo simulations, and quantitative structure-property relationships (QSPR) are utilized to elucidate drug-excipient interactions, predict drug solubility, and understand drug release kinetics, thereby accelerating formulation design [10].

Conclusion

This collection of research explores advanced strategies in pharmaceutical formulation and drug delivery. It highlights the rational design of nanomedicines for targeted delivery, emphasizing the engineering of nanoparticles to improve therapeutic efficacy and reduce toxicity. The use of self-assembled nanostructures like liposomes and polymeric micelles for hydrophobic drugs is discussed, alongside stimuli-responsive systems for controlled drug release. The importance of the biopharmaceutical classification system (BCS), solid-state properties of drugs, and the role of excipients in amorphous solid dispersions for enhancing bioavailability are examined. Furthermore, the application of porous materials, the challenges in oral delivery of biologics, and the impact of particle size and morphology on drug performance are covered. Finally, the integration of computational modeling in molecular pharmaceutics for formulation design is presented. Collectively, these studies underscore the critical interplay between molecular properties, formulation strategies, and drug delivery outcomes.

References

1. Wei, Yan, Wang. (2023) .Nanomedicine 18:134-149.

   , ,

2. Balamurali, Reddy, Chandra. (2022) .ACS Nano 16:12138-12150.

   , ,

3. Wang, Li, Zhang. (2021) .Journal of Controlled Release 520:345-358.

   , ,

4. Dixit, Pakhale, Chaudhari. (2024) .International Journal of Pharmaceutics 652:113780.

   , ,

5. Datta, Ganguly, Mitragotri. (2023) .Journal of Pharmaceutical Sciences 112:189-205.

   , ,

6. Zhang, Lu, Sun. (2022) .Expert Opinion on Drug Delivery 19:953-970.

   , ,

7. Mao, Liu, Chen. (2023) .Materials Today 62:45-59.

   , ,

8. Hu, Wu, Wang. (2022) .Advanced Drug Delivery Reviews 180:234-250.

   , ,

9. Pham, Tran, Nguyen. (2024) .European Journal of Pharmaceutics and Biopharmaceutics 195:100-115.

   , ,

10. Zhou, Zhang, Gao. (2023) .Molecular Pharmaceutics 20:4567-4580.

    , ,